Modulation of CCR5 density with low doses of the transplant drug Rapamycin sensitizes Vicriviroc-resistant R5 HIV-1

被引：0
|
作者：
Heredia, Alonso [1 ]
机构：
[1] Inst Human Virol, Baltimore, MD USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2009年 / 51卷
关键词：
D O I：
10.1097/01.qai.0000351153.08940.9f
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
198
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [1] Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
    Pugach, Pavel
    Ray, Neelanjana
    Klasse, Per Johan
    Ketas, Thomas J.
    Michael, Elizabeth
    Doms, Robert W.
    Lee, Benhur
    Moore, John P.
    VIROLOGY, 2009, 387 (02) : 296 - 302
  • [2] The reduction in density of CCR5 coreceptors by rapamycin improves Vicriviroc antiviral activity on HIV-1
    Boulestin, A.
    VIROLOGIE, 2009, 13 (02) : 118 - 118
  • [3] A vicriviroc-resistant HIV-1 subtype C clinical isolate depends strongly on the second extracellular loop of CCR5 for entry
    Henrich, T. J.
    Lewine, N. R. P.
    Lin, N.
    Ratner, L.
    Sagar, M.
    Tsibris, A. M. N.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2010, 15 : A77 - A77
  • [4] Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Heredia, Alonso
    Latinovic, Olga
    Gallo, Robert C.
    Melikyan, Gregory
    Reitz, Marv
    Le, Nhut
    Redfield, Robert R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (51) : 20476 - 20481
  • [5] Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection
    Lin, YL
    Mettling, C
    Portales, P
    Reynes, J
    Clot, J
    Corbeau, P
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) : 15590 - 15595
  • [6] Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines:: An approach to suppress R5 strains of HIV-1
    Heredia, A
    Amoroso, A
    Davis, C
    Le, N
    Reardon, E
    Dominique, JK
    Klingebiel, E
    Gallo, RC
    Redfield, RR
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) : 10411 - 10416
  • [7] Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
    Kuemmerle, Tim
    Lehmann, Clara
    Hartmann, Pia
    Wyen, Christoph
    Faetkenheuer, Gerd
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1773 - 1785
  • [8] CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Heredia, Alonso
    Gilliam, Bruce
    DeVico, Anthony
    Le, Nhut
    Bamba, Douty
    Flinko, Robin
    Lewis, George
    Gallo, Robert C.
    Redfield, Robert R.
    AIDS, 2007, 21 (10) : 1317 - 1322
  • [9] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
    Henrich, T. J.
    Lewine, N.
    Lee, S-H
    Rao, S.
    Berro, R.
    Greaves, W.
    Gulick, R.
    Tsibris, A.
    Moore, J.
    Kuritzkes, D.
    ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
  • [10] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
12345